Contineum Shares Fall After Phase 2 PIPE-307 Trial Fails to Meet Efficacy Goals in Multiple Sclerosis

MT Newswires Live11-22

Contineum Therapeutics (CTNM) shares were down about 10% in recent Friday trading after the company said late Thursday that its phase 2 trial of PIPE-307, in development for the treatment of patients with relapsing-remitting multiple sclerosis, failed to meet its primary and secondary efficacy goals.

The company said PIPE-307 showed an acceptable safety and tolerability profile. Contineum said it is continuing to analyze exploratory endpoints and plans to present the full dataset at a future medical meeting.

The company said it remains committed to pursuing novel therapies for patients with inflammatory and fibrotic diseases.

Price: 10.93, Change: -1.29, Percent Change: -10.56

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2585276123?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-22 04:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2585276123","market":"hk","top_or_hot":-1,"title":"Contineum Shares Fall After Phase 2 PIPE-307 Trial Fails to Meet Efficacy Goals in Multiple Sclerosis","media":"MT Newswires Live","content":"<html><body><p> Contineum <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (CTNM) shares were down about 10% in recent Friday trading after the company said late Thursday that its phase 2 trial of PIPE-307, in development for the treatment of patients with relapsing-remitting multiple sclerosis, failed to meet its primary and secondary efficacy goals.</p><p>The company said PIPE-307 showed an acceptable safety and tolerability profile. Contineum said it is continuing to analyze exploratory endpoints and plans to present the full dataset at a future medical meeting.</p><p>The company said it remains committed to pursuing novel therapies for patients with inflammatory and fibrotic diseases.</p><p>Price: 10.93, Change: -1.29, Percent Change: -10.56</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Contineum Shares Fall After Phase 2 PIPE-307 Trial Fails to Meet Efficacy Goals in Multiple Sclerosis</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nContineum Shares Fall After Phase 2 PIPE-307 Trial Fails to Meet Efficacy Goals in Multiple Sclerosis\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-11-22 04:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Contineum <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (CTNM) shares were down about 10% in recent Friday trading after the company said late Thursday that its phase 2 trial of PIPE-307, in development for the treatment of patients with relapsing-remitting multiple sclerosis, failed to meet its primary and secondary efficacy goals.</p><p>The company said PIPE-307 showed an acceptable safety and tolerability profile. Contineum said it is continuing to analyze exploratory endpoints and plans to present the full dataset at a future medical meeting.</p><p>The company said it remains committed to pursuing novel therapies for patients with inflammatory and fibrotic diseases.</p><p>Price: 10.93, Change: -1.29, Percent Change: -10.56</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PIPE","symbol_name":"Invesco SteelPath MLP & Energy Infrastructure ETF","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2585276123","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2585276123","pubTimestamp":1763756289,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Contineum Therapeutics  shares were down about 10% in recent Friday trading after the company said late Thursday that its phase 2 trial of PIPE-307, in development for the treatment of patients with relapsing-remitting multiple sclerosis, failed to meet its primary and secondary efficacy goals.The company said PIPE-307 showed an acceptable safety and tolerability profile. Contineum said it is continuing to analyze exploratory endpoints and plans to present the full dataset at a future medical meeting.The company said it remains committed to pursuing novel therapies for patients with inflammatory and fibrotic diseases.Price: 10.93, Change: -1.29, Percent Change: -10.56","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PIPE":"Invesco SteelPath MLP & Energy Infrastructure ETF","CTNM":"Contineum Therapeutics, INC.","BK4007":"制药"},"translate_title":"2期PIPE-307试验未能达到多发性硬化症疗效目标后，Contineum股价下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CTNM":1,"PIPE":1.5},"content_text":"Contineum Therapeutics (CTNM) shares were down about 10% in recent Friday trading after the company said late Thursday that its phase 2 trial of PIPE-307, in development for the treatment of patients with relapsing-remitting multiple sclerosis, failed to meet its primary and secondary efficacy goals.The company said PIPE-307 showed an acceptable safety and tolerability profile. Contineum said it is continuing to analyze exploratory endpoints and plans to present the full dataset at a future medical meeting.The company said it remains committed to pursuing novel therapies for patients with inflammatory and fibrotic diseases.Price: 10.93, Change: -1.29, Percent Change: -10.56","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2585276123","isCrawlerRequest":true}